How do Zoloft (sertraline) and Prozac (fluoxetine) differ?

Zoloft and Prozac: Key Differences

Zoloft (sertraline) and Prozac (fluoxetine) are both SSRIs with equivalent efficacy for treating depression, but they differ primarily in their side effect profiles and drug interaction potential—specifically, sertraline has a higher rate of diarrhea while fluoxetine causes more drug-drug interactions through CYP2D6 inhibition. 1

Efficacy: Essentially Equivalent

Based on American College of Physicians guidelines, there are no clinically significant differences in efficacy between sertraline and fluoxetine for treating major depressive disorder 1. Both medications:

• Show similar response and remission rates in head-to-head trials
• Work equally well across different patient subgroups (age, sex, race)
• Have comparable effectiveness for treating accompanying anxiety symptoms 1

One nuanced finding: In patients with severe depression specifically, sertraline may offer a slight advantage (CGI-I responder rates 88% vs 71%, P=0.03), though this comes from pooled analysis rather than individual trials 2.

Side Effect Profile Differences

Gastrointestinal Effects

Sertraline causes significantly more diarrhea than fluoxetine (and most other SSRIs) 1. This is the most consistent distinguishing adverse effect between the two medications.

Sexual Dysfunction

Both medications cause sexual side effects at similar rates. Fluoxetine and sertraline have lower rates of sexual dysfunction compared to paroxetine, but higher rates than bupropion 1.

Common Side Effects (Similar Between Both)

• Nausea (most common reason for discontinuation)
• Headache
• Insomnia
• Dizziness
• Somnolence

1

Drug Interaction Profile: Critical Difference

This is where the medications differ most substantially in clinical practice:

Fluoxetine

• Strong CYP2D6 inhibitor at therapeutic doses
• Significantly increases levels of drugs metabolized by CYP2D6
• Requires dose adjustments when combined with tricyclic antidepressants, certain antipsychotics, beta-blockers, and other CYP2D6 substrates
• Long half-life (including active metabolite norfluoxetine) provides protection against withdrawal symptoms but prolongs drug interactions

3

Sertraline

• Minimal CYP enzyme inhibition at therapeutic doses
• Much lower risk of clinically significant drug-drug interactions
• Safer choice when polypharmacy is necessary
• Does not require routine dose adjustments of co-administered medications

3

Clinical Pitfall: Despite predictable differences in CYP2D6 inhibition, prescribers often fail to adjust doses of "victim drugs" (like TCAs) when switching between these medications. Analysis of VA prescribing patterns showed no dose adjustments were made for drugs with narrow therapeutic indices when co-prescribed with fluoxetine versus sertraline, despite the clear pharmacokinetic differences 3.

Dosing Considerations

Fluoxetine

• Standard starting and maintenance dose: 20 mg/day
• 76% of patients remain on starting dose 4

Sertraline

• Manufacturer's recommended starting dose: 50 mg/day
• However, 47-68% of patients require dose increases above 50 mg to achieve remission 5
• Many clinicians start at or rapidly titrate to 100 mg/day
• Dose-response relationship shows increasing efficacy up to 150 mg, with adverse effects increasing above this threshold 6

Clinical Pitfall: The 50 mg starting dose of sertraline is frequently inadequate for full symptom resolution. Don't hesitate to increase the dose if response is partial 5.

Special Populations

Pregnancy

Current evidence shows both medications have small absolute risks for congenital anomalies. While some older data suggested slightly higher risk with fluoxetine for specific cardiac defects, the absolute risk remains small 7. NICE guidelines favor sertraline during pregnancy, but emphasize that women already benefiting from fluoxetine should not be switched solely due to pregnancy 7.

Adolescents

Fluoxetine is the only SSRI with FDA approval for treating moderate to severe depression in adolescents aged 8-18 years 7.

Clinical Decision Algorithm

Choose Sertraline when:

• Patient takes multiple medications (lower drug interaction risk)
• Polypharmacy with CYP2D6 substrates
• Patient needs flexibility for dose titration
• Diarrhea is not a concern

Choose Fluoxetine when:

• Treating adolescent depression (only FDA-approved SSRI)
• Patient has history of medication non-adherence (long half-life provides forgiveness for missed doses)
• Patient previously responded well to fluoxetine
• Diarrhea is a concern

Both are equivalent for:

• First-line treatment of depression in adults
• Patients with comorbid anxiety
• Elderly patients
• Patients across all demographic groups